Kurzfassung

Most esophageal squamous cell cancer patients have advanced disease at time of diagnosis. Chemotherapy is used to improve quality of life and overall survival, but still with limited impact. Prior studies suggested increased efficacy of EGFR antibodies combined with Cisplatin/5-FU.
We go along with the study since beginning, with organization of the translational research program, sample coordination and analysis of the FFPE tissue and blood material.
The present challenge in this project is to...Most esophageal squamous cell cancer patients have advanced disease at time of diagnosis. Chemotherapy is used to improve quality of life and overall survival, but still with limited impact. Prior studies suggested increased efficacy of EGFR antibodies combined with Cisplatin/5-FU.
We go along with the study since beginning, with organization of the translational research program, sample coordination and analysis of the FFPE tissue and blood material.
The present challenge in this project is to understand the prevalence and incidence of EGFR as target in esophageal cancer therapy.
Thus, the evaluation of the different prognostic and predictive IHC biomarkers and serum levels of cancer associated proteins in terms of overall (OS) and progression free survival (PFS) is warranted.
 » weiterlesen» einklappen